We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Newer Therapies at Last Offer Systemic Options for Metastatic HCC.
- Authors
Ross, Nicole
- Abstract
The article highlights options for treating early-stage disease include liver-directed therapies and surgical resections. It mentions about the approval of Nivolumab and pembrolizumab as second-line therapies in which ramucirumab approved as monotherapy and also highlights the option of liver resection surgery for patients with tumors.
- Subjects
ANTINEOPLASTIC agents; THERAPEUTIC use of monoclonal antibodies; CANCER patients; HEPATOCELLULAR carcinoma; METASTASIS; ORAL drug administration; PATIENT monitoring; UNITED States. Food &; Drug Administration; DRUG approval; PROTEIN kinase inhibitors; THERAPEUTICS
- Publication
ONS Voice, 2019, Vol 34, Issue 12, p30
- ISSN
2475-6938
- Publication type
Article